SS-31 / Elamipretide

Clinical maturity: Approved for one rare disease; investigational or unestablished elsewhere

The approved product (Forzinity) is a subcutaneous injection studied specifically in Barth syndrome. Route, dose and population are tied to that programme; nothing transfers to anti-ageing use.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

A small peptide that concentrates in mitochondria and binds cardiolipin, a lipid essential to the structure of the inner mitochondrial membrane and to efficient energy production.

• Restores youthful mitochondrial function
• Improves endurance and recovery
• Slows ageing
• Improves heart and kidney outcomes

This is a textbook case of why 'approved' needs a footnote. Elamipretide has real human data and a genuine accelerated approval in a rare mitochondrial disease. Trials in broader indications — including some cardiac and ophthalmic programmes — have produced mixed or unsuccessful results. General anti-ageing and performance use is unestablished.

• Clinical trial programme in Barth syndrome supporting accelerated approval.
• Mixed results across trials in primary mitochondrial myopathy and other indications.
• No trials supporting healthy-ageing or athletic-performance claims.

• Strong animal and cell evidence for improved mitochondrial respiration and reduced oxidative stress.
• Models of ischaemia-reperfusion injury, heart failure and age-related muscle decline.

Animal and cell findings are Level 1–2 evidence.

• Binds cardiolipin, stabilising cristae structure in the inner mitochondrial membrane.
• Improves electron transport chain efficiency and reduces reactive oxygen species leakage.

• Injection-site reactions are commonly reported in trials.
• Human safety data exist for studied indications and doses — a meaningful advantage over most research peptides.
• Safety in healthy people using it for performance is not established.

On 19 September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) injection to improve muscle strength in patients with Barth syndrome weighing at least 30 kg — based on a surrogate endpoint, with a confirmatory trial still required. That approval says nothing about general anti-ageing, athletic or longevity use, where it remains unapproved and unestablished.

• 2025-09-19 · United States

  FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg, on a surrogate endpoint with a confirmatory trial required. Does not cover anti-ageing or performance use.

• L4Strong humanBarth syndrome clinical programme

  Randomised and open-label extension — Patients with a rare mitochondrial genetic disease

  Supported accelerated approval in that narrow indication only.

• Positive confirmatory trials in broader indications.
• Any controlled trial in healthy ageing populations.

• Regulatory / labelFDA press release — Accelerated approval of Forzinity (elamipretide) as first treatment for Barth syndrome (19 September 2025)

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

1. 2026-07-05

   Baseline entry: split rating into approved narrow indication versus general anti-ageing claims.

   L3Early humanRating movedBaseline entry
   A rare-disease accelerated approval justifies a higher regulatory status but not higher confidence in longevity or performance claims. The registry now separates the two explicitly.